Most recent articles on targeted therapy in ovarian cancer
- From: scimedweb@xxxxxxxx
- Date: Wed, 25 Feb 2009 01:30:31 -0800 (PST)
Most recent articles on targeted therapy in ovarian cancer:
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in
ovarian clear cell adenocarcinoma.
Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi
S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M,
Osamura RY.
Pathol Int. 2009 Jan;59(1):19-27.
Lack of reliability of CA125 response criteria with anti-VEGF
molecularly targeted therapy.
Markman M.
Cancer. 2008 Nov 15;113(10):2832-3.
HER receptor signaling confers resistance to the insulin-like growth
factor-I receptor inhibitor, BMS-536924.
Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong
TW, Gottardis MM, Erlichman C.
Mol Cancer Ther. 2008 Sep;7(9):2589-98.
Combination targeted therapy with sorafenib and bevacizumab results in
enhanced toxicity and antitumor activity.
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata
CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow
C, Chen HX, Wright JJ, Figg WD, Kohn EC.
J Clin Oncol. 2008 Aug 1;26(22):3709-14. Erratum in: J Clin Oncol.
2008 Sep 10;26(26):4363.
Future directions in the management of epithelial ovarian cancer.
Blagden S, Gabra H.
Future Oncol. 2008 Jun;4(3):403-11.
First-line randomized trials: revisiting the Ptolemaic universe.
Bookman MA.
Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:47-52.
Lack of reliability of CA125 response criteria with anti-VEGF
molecularly targeted therapy.
Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C,
Kotz HL, Kohn EC.
Cancer. 2008 Apr 15;112(8):1726-32.
Impact of vessel maturation on antiangiogenic therapy in ovarian
cancer.
Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings
NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB,
Coleman RL, Sood AK.
Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10.
LHRH receptor targeted therapy for breast cancer.
Kakar SS, Jin H, Hong B, Eaton JW, Kang KA.
Adv Exp Med Biol. 2008;614:285-96.
The emerging role of epidermal growth factor receptor inhibitors in
ovarian cancer.
Palayekar MJ, Herzog TJ.
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):879-90.
InTextoResearch, Baelen, Wallonie (Wallonia), Belgique (Belgium) &
Agence Wallonne d’Information Scientifique (AWIS) (Marc Lacroix,
scimedweb@xxxxxxxx)
.
- Prev by Date: This Week's NCI Cancer Bulletin: Feb. 24, 2009
- Next by Date: Most recent articles on targeted therapy in prostate cancer
- Previous by thread: This Week's NCI Cancer Bulletin: Feb. 24, 2009
- Next by thread: Most recent articles on targeted therapy in prostate cancer
- Index(es):
Relevant Pages
|
